Therapeutic strategies against peritoneal metastasis from gastric cancer (GCPM) are limited. Woo and colleagues established a novel syngeneic ACKPY3944-ffluc-GCPM mouse model to test the efficacy of IP CF17 OV treatment. Results showed that CF17 enhanced antitumor activity, immunogenicity, and survival in these mice, supporting its role as a promising immunotherapy for GCPM.
